Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme

• Published in: Diabetic medicine 2011-03, Vol.28 (3), p.345-351
• Main Authors: Sjølie, A. K., Klein, R., Porta, M., Orchard, T., Fuller, J., Parving, H. H., Bilous, R., Aldington, S., Chaturvedi, N.
• Format: Article
• Language: English
• Subjects: Adult; Aneurysm - complications; Aneurysm - drug therapy; Aneurysm - physiopathology; Angiotensin II Type 1 Receptor Blockers - therapeutic use; angiotensin receptor blocker; Benign; Benzimidazoles - therapeutic use; Biological and medical sciences; candesartan; Clinical trials; Diabetes mellitus; Diabetes Mellitus, Type 1 - complications; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 1 - physiopathology; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - physiopathology; Diabetes. Impaired glucose tolerance; diabetic retinopathy; Diabetic Retinopathy - complications; Diabetic Retinopathy - drug therapy; Diabetic Retinopathy - physiopathology; Disease Progression; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Feeding. Feeding behavior; Female; Fundamental and applied biological sciences. Psychology; Humans; Hypoglycemic Agents - therapeutic use; Male; Medical sciences; microaneurysms; Middle Aged; Predictive Value of Tests; Regression (Psychology); Remission Induction; Retina; Retinal Diseases - drug therapy; Retinal Diseases - etiology; Retinal Diseases - physiopathology; Retinopathy; Tetrazoles - therapeutic use; Vertebrates: anatomy and physiology, studies on body, several organs or systems; Vertebrates: endocrinology
• ISSN: 0742-3071; 1464-5491
• DOI: 10.1111/j.1464-5491.2010.03210.x

Diabet. Med. 28, 345–351 (2011) Objective  To study the association between baseline retinal microaneurysm score and progression and regression of diabetic retinopathy, and response to treatment with candesartan in people with diabetes. Methods  This was a multicenter randomized clinical trial. The progression analysis included 893 patients with Type 1 diabetes and 526 patients with Type 2 diabetes with retinal microaneurysms only at baseline. For regression, 438 with Type 1 and 216 with Type 2 diabetes qualified. Microaneurysms were scored from yearly retinal photographs according to the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Retinopathy progression and regression was defined as two or more step change on the ETDRS scale from baseline. Patients were normoalbuminuric, and normotensive with Type 1 and Type 2 diabetes or treated hypertensive with Type 2 diabetes. They were randomized to treatment with candesartan 32 mg daily or placebo and followed for 4.6 years. Results  A higher microaneurysm score at baseline predicted an increased risk of retinopathy progression (HR per microaneurysm score 1.08, P